Atara Biotherapeutics (ATRA) vs Biomea Fusion (BMEA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomea Fusion (BMEA) has outperformed Atara Biotherapeutics (ATRA) over the past year, losing 18.5% versus a loss of 41.8%. Over five years, BMEA leads with a -88.2% price change compared with -97.6% for ATRA. Biomea Fusion is the larger company by market cap ($99.1 million vs $92.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | BMEA |
|---|---|---|
| Share price | $9.23 | $1.37 |
| Market cap | $92.65M | $99.05M |
| 1-day change | -1.49% | +3.79% |
| YTD return | -48.98% | +10.48% |
| 1-year return | -41.77% | -18.45% |
| 5-year return | -97.56% | -88.22% |
| Forward P/E | 5.97 | — |
| EPS (TTM) | $-1.30 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.15 | $2.24 |
| 52-week low | $3.92 | $0.872 |
| Distance from 52-week high | -51.79% | -38.76% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +48.10% | +410.95% |
| Average volume | 53.79K | 1.47M |
| Shares outstanding | 10.04M | 72.30M |
| Employees | 10 | 37 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMEA has outperformed ATRA by 23.3 percentage points over the past year.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Healthcare · Biotechnology · 10 employees
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Healthcare · Biotechnology · 37 employees
ATRA vs BMEA FAQ
Which is bigger, Atara Biotherapeutics or Biomea Fusion?
Biomea Fusion (BMEA) is larger, with a market capitalization of $99.05M compared with $92.65M for Atara Biotherapeutics (ATRA).
Which stock has performed better over the past year, ATRA or BMEA?
BMEA returned -18.45% over the past 12 months, compared with -41.77% for ATRA (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Biomea Fusion in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.